- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
May 11, 2017
Dr. Lynn Morris, head of HIV Virology at South Africa’s National Institute for Communicable Diseases and professor at the University of the Witwatersrand in Johannesburg, provided an overview of antibody research for HIV prevention. She laid out the current landscape; provided a glimpse of what is to come in this dynamic field; talked about where antibody work fits in the larger field of prevention research; and described how the Antibody Mediated Prevention (AMP) studies – ongoing proof-of-concept trials of the broadly neutralizing antibody VRC01 – might advance HIV prevention.
This was the fourth in our series of HIV Vaccine Awareness Day webinars. For details on the full series, visit avac.org/hvad.